Aspen Neuroscience begins third cohort in ASPIRO trial

Aspen Neuroscience has launched Cohort 3 of its ASPIRO Phase 1/2a clinical trial for ANPD001, its autologous dopaminergic neuronal precursor cell (DANPC) therapy for Parkinson’s disease, the company announced. Cohort 3 marks the first use of Aspen’s commercial formulation of ANPD001, which the company said is designed to enable scalable, reproducible manufacturing and seamless clinical […] The post Aspen Neuroscience begins third cohort in ASPIRO trial appeared first on Longevity.Technology.